Navigation Links
Alexza to Announce 2011 Third Quarter Financial Results on Monday, November 7, 2011
Date:10/27/2011

re information about Alexza, the Staccato system technology or the Company's development programs, please visit www.alexza.com.

Safe Harbor Statement

The anticipated news release and conference call will contain forward-looking statements that involve significant risks and uncertainties. Any statement describing the Company's expectations or beliefs is a forward-looking statement, as defined in the Private Securities Litigation Reform Act of 1995, and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of developing and commercializing drugs, including the adequacy of the Company's capital to support the Company's operations, the potential of the Company's ADASUVE NDA resubmission to adequately address the issues in the Complete Response Letter, the timing of the FDA's review of the NDA, the eventual prospects that ADASUVE will be approved for marketing in the U.S., and the timing and prospects for regulatory approval to market ADASUVE in Europe, Latin America, Russia and the Commonwealth of Independent States countries. The Company's forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements. These and other risks concerning Alexza's business are described in additional detail in the Company's Annual Report on Form 10-K for the year ended December 31, 2010, and the Company's other Periodic and Current Reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
2. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
3. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
4. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
5. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
6. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
7. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
8. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
9. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
10. Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
11. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... , July 7, 2015 Noting the need ... pricing policies currently practiced by the rapidly consolidating pharmacy ... (SCPC) today praised Ohio Governor ... a new state effort to help pull back the ... "We applaud Governor Kasich for bringing badly-needed ...
(Date:7/7/2015)... , July 7, 2015 Biobanks ... Helping Your Influence  ,Are you interested ... so, now gain technological and commercial predictions from 2015. ... explore trends in research and development, results, opportunities and ... visiongain shows you what,s possible for biobanking and ...
(Date:7/7/2015)... , 7. Juli 2015 ... -Technik für klinische Studien, gab heute bekannt, dass ... führendes Unternehmen bei Gewinnung und Erhalt von Patienten ... Tochtergesellschaften MediciGlobal , Ltd. und Access to ... auch einen Dienst zum Auffinden von Patienten, die ...
Breaking Medicine Technology:National LTC Pharmacy Leader Praises Kasich Effort to Bring Transparency to PBM Drug Pricing 2National LTC Pharmacy Leader Praises Kasich Effort to Bring Transparency to PBM Drug Pricing 3Biobanking for Medicine: Technology, Industry and Market 2015-2025 2Biobanking for Medicine: Technology, Industry and Market 2015-2025 3Biobanking for Medicine: Technology, Industry and Market 2015-2025 4Biobanking for Medicine: Technology, Industry and Market 2015-2025 5Biobanking for Medicine: Technology, Industry and Market 2015-2025 6Biobanking for Medicine: Technology, Industry and Market 2015-2025 7Biobanking for Medicine: Technology, Industry and Market 2015-2025 8Biobanking for Medicine: Technology, Industry and Market 2015-2025 9Biobanking for Medicine: Technology, Industry and Market 2015-2025 10BioClinica übernimmt MediciGroup 2BioClinica übernimmt MediciGroup 3BioClinica übernimmt MediciGroup 4
... Held at 9:00 a.m. Eastern Time Today, May 26, ... (Nasdaq: UTHR ) announced today that the ... ADCIRCA(TM) (tadalafil) tablets for oral administration, with a recommended ... type 5 (PDE5) inhibitor for the treatment of pulmonary ...
... 23 Amid all the speculation over what course ... Replikins Ltd. ( www.replikins.com ) last week ... and determined that the infectivity of the H1N1 virus ... low for the immediate future.The company,s quantitative analysis of ...
Cached Medicine Technology:FDA Approves ADCIRCA(TM) (Tadalafil) Tablets for the Treatment of Pulmonary Arterial Hypertension 2FDA Approves ADCIRCA(TM) (Tadalafil) Tablets for the Treatment of Pulmonary Arterial Hypertension 3FDA Approves ADCIRCA(TM) (Tadalafil) Tablets for the Treatment of Pulmonary Arterial Hypertension 4Swine Flu (H1N1) Infectivity to Increase Markedly and Lethality to Remain Low According to Latest Replikin* Peptide Genomic Data 2
(Date:7/7/2015)... ... July 07, 2015 , ... Owners of Green Ladies ... winners in the home service category. This honor can only be gained by votes ... of the safety of the products and methods they use daily. Having a home ...
(Date:7/7/2015)... ... 2015 , ... Difass USA, a modern supplement brand committed to excellence, understands ... work is knowing that there is hopefully a vacation to look forward to this ... Planning for a vacation can be quite stressful, and it’s difficult sometimes to fully ...
(Date:7/7/2015)... Angeles, CA (PRWEB) , ... July 07, 2015 ... ... International Business Times highlights rumors about possible facial rejuvenation that have emerged about ... year-old former U.S. Secretary of State looks more youthful than she has in ...
(Date:7/7/2015)... ... July 07, 2015 , ... Greatist today ... website that helps active people find the most fun activities to do with friends. ... for millennials. It also increases Greatist’s opportunity for events, e-commerce, and brand partnerships. , ...
(Date:7/7/2015)... , ... July 07, 2015 , ... ... industry group whose board is limited to permit holders. The Medical Cannabis Alliance ... to move the industry forward and are committed to making sure patients have ...
Breaking Medicine News(10 mins):Health News:Environmentally-Friendly House Cleaning Company Wins Best of Madison Magazine Award 2Health News:Difass USA Offers Eight Tips to Help Relax and Enjoy Summer Vacation 2Health News:Difass USA Offers Eight Tips to Help Relax and Enjoy Summer Vacation 3Health News:Recent Article on Hillary Clinton Plastic Surgery Speculation Illuminates the Reasons Many Professionals Explore Facial Rejuvenation, says Dr. J 2Health News:Recent Article on Hillary Clinton Plastic Surgery Speculation Illuminates the Reasons Many Professionals Explore Facial Rejuvenation, says Dr. J 3Health News:Greatist Acquires Active Lifestyle Brand Blood, Sweat & Cheers 2Health News:Cannabis Growers and Dispensaries Form Medical Cannabis Alliance of Illinois 2
... , Montreal, May 28, 2009 Sipping wine, beer ... risk of binge drinking, particularly among young men, according to ... Researchers from the Universit de Montral and the University of ... that frequent alcohol consumption can lead to binge drinking among ...
... package testing services firm specializing in medical device package testing, will be ... will help kick off the conference with a powerful presentation by Scotty ... ... -- DDL , the leading package testing services firm specializing in ...
... the Building Owners and Managers Association (BOMA) Southwest ... HeartSine Technologies announced the donation of thirteen HeartSine ... associations of the BOMA Southwest Region. These ... Oklahoma. Because one American dies approximately every two ...
... Early Helps Identify Developmental Delays and Promote GrowthNEW ORLEANS, ... 10:30am - 11:30am , at 1315 Jefferson ... will "Reach Out and Read " with Louisiana,s ... childhood literacy program. In this initiative, pediatricians encourage parents ...
... 28 Aventis Pharmaceutical Inc., a wholly owned subsidiary of ... $95.5 million to settle allegations that it violated the False ... its Medicaid Drug Rebate obligations, the Justice Department announced today. ... The settlement resolves allegations that between 1995 ...
... YORK, May 28 Kyowa Hakko U.S.A., Inc. (Kyowa ... Bio Co., Ltd., (Kyowa), has announced it has completed ... brain health ingredient Cognizin(R) Citicoline. Cognizin(R) is a branded ... cell of the body. Citicoline provides an essential ...
Cached Medicine News:Health News:Daily alcohol intake can lead to binge drinking 2Health News:DDL, Leader in Medical Device Package, Product and Material Testing, will be Presenting at This Year's MD&M Show in New York 2Health News:HeartSafe and HeartSine Announce AED Donation Program to Local BOMA Associations 2Health News:Ochsner Introduces Literacy Program to Promote Healthy Minds 2Health News:Aventis Pharmaceutical to Pay U.S. $95.5 Million to Settle False Claims Act Allegations 2Health News:Kyowa Hakko USA Announces GRAS Self-Affirmation for Novel Brain Health Ingredient Cognizin(R) Citicoline 2
... The Mayo Clinic Elbow Brace, featuring an ... exceptional stability and comfort while allowing for ... of the elbow. The sturdy metal uprights ... securely hold the brace in position, ensure ...
... Elbow Orthosis applies dynamic low-loaded force ... Controls elbow contracture in patients with ... Also good for elbow flexion and ... to apply tension (but not torque) ...
... Aircast aircell technology enables the Pneumatic Armband ... a single pre-inflated aircell, the Armband concentrates ... around the arm, for more support and ... the Armband is designed to conform to ...
... Brace is designed to add the therapeutic ... (sold separately). When inserted into the PneumaticWalker ... surrounds the foot and ankle with soothing ... and pain.,All Cryo/Cuffs can be ordered as ...
Medicine Products: